Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells.

Oncotarget - 18 Jul 2017

Mukherjee Nabanita, Lu Yan, Almeida Adam, Lambert Karoline, Shiau Chung-Wai, Su Jung-Chen, Luo Yuchun, Fujita Mayumi, Robinson William A, Robinson Steven E, Norris David A, Shellman Yiqun G

Abstract excerpt

MCL-1 (BCL-2 family anti-apoptotic protein) is responsible for melanoma's resistance to therapy. Cancer initiating cells also contribute to resistance and relapse from treatments. Here we examined the effects of the MCL-1 inhibitor SC-2001 in killing non melanoma-initiating-cells (bulk of melanoma), and melanoma-initiating-cells (MICs). By itself, SC-2001 significantly kills melanoma cells under monolayer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bcl-2-Like Protein 11
Share to Biphenyl Compounds

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Self Renewal

Share to Drug Synergism

Share to Melanocytes

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Nitrophenols

Share to Pyrroles

Source

Open in PubMed Open full text

Identifiers

PMID: 27086916
DOI: 10.18632/oncotarget.8695
PMCID: PMC5564524

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells.PMID 27086916Read ↗

Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.Semantic proximity Read ↗

IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition processSemantic proximity Read ↗

Therapy of metastatic malignant melanoma: on the way to individualized disease control.Semantic proximity Read ↗

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsSemantic proximity Read ↗

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survivalSemantic proximity Read ↗

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.Semantic proximity Read ↗

Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.Semantic proximity Read ↗

BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells.Semantic proximity Read ↗

<i>BCL2A1</i> is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibitionSemantic proximity Read ↗

Role of the pro-survival molecule Bfl-1 in melanoma.Semantic proximity Read ↗

No longer a molecular black box--new clues to apoptosis and drug resistance in melanoma.Semantic proximity Read ↗

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.